Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 141–150, page 15 of 20. Filter these by subject, year and score in the research library →
-
Real-world safety and implementation challenges of lecanemab therapy for Alzheimer's disease in South Korea: a single-center experienceResearch summary
Research summaries · alzhub.org/study/real-world-safety-and-implementation-challenges-of-lecanemab-therapy-42449395
Lecanemab, an amyloid-targeting monoclonal antibody, was recently approved for early symptomatic Alzheimer's disease in South Korea. Asians were underrepresented in prior trials, and real-world data from Korea remain scarce, …
-
The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation ModelingResearch summary
Research summaries · alzhub.org/study/the-potential-economic-value-of-lecanemab-in-patients-with-early-35718854
… study aimed to model lecanemab, a humanized monoclonal antibody targeting amyloid protofibrils, for patients with early AD, and estimate the potential value-based price (VBP) of lecanemab + standard of care (SoC) compared to SoC …
-
Research summaries · alzhub.org/study/transitioning-from-clinical-trial-to-clinical-practice-for-long-term-42872652
Introduction/background Lecanemab, an anti-amyloid monoclonal antibody, significantly reduces amyloid markers and slows clinical decline in early Alzheimer's disease (AD) clinical trials. We assessed our single-center experience …
-
Research summaries · alzhub.org/study/baseline-physical-frailty-predicts-clinical-outcomes-during-lecanemab-42970319
… with early AD receiving lecanemab. Methods This prospective cohort included 187 patients with amyloid-positive early AD who initiated lecanemab at a tertiary memory clinic. Physical frailty was defined using the Short Physical …
-
Research summaries · alzhub.org/study/lecanemab-adoption-and-geographic-variation-among-patients-with-41433980
Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion. Women consisted of 53.1% the infusion …
-
Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatmentResearch summary
Research summaries · alzhub.org/study/lower-baseline-cerebrospinal-fluid-amyloid-42-is-associated-with-42742530
… safety concern during lecanemab treatment for early Alzheimer's disease. We examined baseline cerebrospinal fluid amyloid-β 42 (Aβ 42 ) in 97 lecanemab-treated patients; 11 developed ARIA. Aβ 42 was lower in ARIA cases than in …
-
Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysisResearch summary
Research summaries · alzhub.org/study/safety-of-lecanemab-in-real-world-patients-with-alzheimer-s-disease-a-42890205
… observational study, lecanemab demonstrated a generally favorable safety profile. Although clinical trials have demonstrated its favorable safety profile, real-world studies are crucial for identifying rare adverse events (AEs) …
-
Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in ChinaResearch summary
Research summaries · alzhub.org/study/determinants-of-treatment-willingness-and-willingness-to-pay-for-40955711
… real-world adoption of lecanemab than clinical efficacy alone. Addressing financial constraints also enhances patients' willingness to pay, informing patient-centred clinical decision pathways. W treat showed a strong direct …
-
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and LecanemabResearch summary
Research summaries · alzhub.org/study/impact-of-anti-amyloid-monoclonal-antibodies-on-the-pathology-and-35493943
… gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. …
-
Research summaries · alzhub.org/study/lecanemab-aducanumab-and-gantenerumab-binding-profiles-to-different-36253511
… binding properties of lecanemab, aducanumab, and gantenerumab to different Aβ species with inhibition ELISA, immunodepletion, and surface plasmon resonance. All three antibodies bound monomers with low affinity. However, …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.